Icu Medical - ICUI STOCK NEWS

ICU Medical (NASDAQ:ICUI) has received FDA 510(k) clearance for its new Plum Solo™ and updated Plum Duo™ precision IV pumps, along with LifeShield™ infusion safety software. These devices introduce a new category of precision IV pumps designed to address delivery variability with ±3% accuracy in real-world conditions.

The single-channel Plum Solo complements the dual-channel Plum Duo, offering healthcare systems flexibility in device configuration. Both pumps feature compatibility with whole blood and blood products, and include advanced features such as full-color touchscreens, simplified drug library management, and IV-EHR interoperability.

This milestone marks ICU Medical's achievement of 5 FDA 510(k) clearances in the past 18 months, with plans to expand their LifeShield platform with next-generation Medfusion™ syringe pump and CADD™ pain and ambulatory pump products.

ICU Medical (Nasdaq:ICUI), a leading medical products innovator, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference, scheduled for April 7-10, 2025.

The company's presentation is set for Monday, April 7, 2025, at 8:00 a.m. PT (11:00 a.m. ET). Management will also engage in one-on-one meetings throughout the day. Investors and interested parties can access the live webcast through the company's website at icumed.com under the Investors tab and Event Calendar section. A replay option will be available for those unable to attend the live presentation.

ICU Medical (Nasdaq:ICUI), a leading medical products innovator, has announced its participation in the upcoming KeyBanc Healthcare Forum, scheduled for March 18-19, 2025. The company will engage in a fireside chat on March 19, 2025, at 8:15 a.m. PT (11:15 a.m. ET).

The event will be held virtually, and company management will also conduct one-on-one meetings throughout the day. Investors and interested parties can access the live webcast through ICU Medical's website at icumed.com under the Investors tab and Event Calendar section. A replay option will be available for those unable to attend the live session.

ICU Medical (NASDAQ:ICUI) reported Q4 2024 financial results with revenue of $629.8 million, up from $587.9 million in Q4 2023. The company's GAAP gross profit increased to $227.3 million with a margin of 36.1%, compared to $171.6 million and 29.2% in the prior year.

Despite revenue growth, ICUI posted a GAAP net loss of $(23.8) million, or $(0.97) per diluted share, wider than the $(17.1) million loss in Q4 2023. However, adjusted metrics showed improvement with adjusted EPS of $2.11 and adjusted EBITDA of $105.5 million, up from $1.57 and $86.3 million respectively.

For fiscal year 2025, ICUI projects GAAP net loss between $(45) million to $(28) million, with adjusted EBITDA guidance of $395-425 million and adjusted EPS of $6.55-7.25. The company's planned IV Solutions joint venture, expected to close in Q2 2025, could reduce 2025 adjusted EBITDA by $15-20 million while remaining neutral to adjusted EPS.

ICU Medical (Nasdaq: ICUI) has announced its schedule for the fourth quarter 2024 earnings release and conference call. The company will release Q4 2024 results on Thursday, February 27, 2025, at approximately 4:00 p.m. ET (1:00 p.m. PT), followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT) on the same day.

Investors can access the call via telephone at (800) 445-7795 using conference ID 'ICUMED'. Additionally, a webcast will be available through the Investors tab on ICU Medical's website at www.icumed.com, with replay options available.

ICU Medical (NASDAQ:ICUI), a leading medical products innovator, has announced its participation in the Raymond James 46th Annual Institutional Investors Conference in Orlando, Florida, scheduled for March 3-5, 2025.

The company's presentation is set for Monday, March 3, 2025, at 5:40 a.m. PT (8:40 a.m. ET). Management will also engage in one-on-one meetings throughout the day. Investors and interested parties can access the live webcast through ICU Medical's website at icumed.com under the Investors tab and Event Calendar section. A replay option will be available for those unable to attend the live presentation.

ICU Medical (ICUI), a leading medical products innovator, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The company's management will deliver a presentation on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET).

The presentation will be accessible through a live webcast on the company's website at icumed.com under the Investors tab and Event Calendar section, with replay options available. Additionally, company management will engage in one-on-one meetings on January 15 and 16, 2025.

ICU Medical (NASDAQ:ICUI) reported Q3 2024 financial results with revenue of $589.1 million, up from $553.3 million year-over-year. The company posted a GAAP net loss of $(33.0) million, or $(1.35) per diluted share, compared to a net income of $7.2 million, or $0.30 per share in Q3 2023. Gross margin improved to 34.8% from 33.2%. Adjusted EBITDA increased to $94.8 million from $89.8 million. The company updated its FY2024 guidance, projecting adjusted EBITDA of $355-365 million and adjusted EPS of $5.40-5.70.

ICU Medical and Otsuka Pharmaceutical Factory have announced a joint venture aimed at strengthening IV solutions manufacturing and innovation in North America. This partnership will create one of the largest global IV solutions manufacturing networks, producing an estimated 1.4 billion units annually. The joint venture will combine OPF's global manufacturing scale with ICU Medical's strong North American production and distribution capabilities, enhancing supply chain resiliency and accelerating new product development. ICU Medical will provide commercial services to ensure seamless operations. The venture is expected to become operational in early Q2 2025. Key economic terms include a $200 million upfront payment from OPF to ICU Medical, performance-based milestones by the end of 2026, and a put-call option in 2030 and beyond. This collaboration aims to address persistent supply chain challenges in the North American IV solutions market and deliver clinical and economic value to customers.